Atrial Fibrillation
Thursday, May 2nd, 2013
J Am Heart Assoc: March 18, 2013 Background In the past decade, catheter ablation has become an established therapy for symptomatic atrial fibrillation (AF). Until very recently, few data have been available to guide the clinical community on the outcomes of AF ablation at ≥3 years of follow‐up. We aimed to systematically review the medical literature to […]
Atrial Fibrillation
Tuesday, April 23rd, 2013
Am Coll Cardiology: April 23, 2013 Objectives The purpose of this study was to investigate long-term outcomes of freedom from atrial fibrillation (AF) after pulmonary vein (PV) isolation using cryoballoon ablation with balloon-size selection based on individual PV diameters. Background Data are lacking on long-term outcomes from cryoablation and on the most effective balloon size. Methods This was […]
Atrial Fibrillation
Tuesday, April 23rd, 2013
Neurology: April 17, 2013 Background: Based on the higher frequency of paroxysmal atrial fibrillation during night and early morning hours, we sought to analyze the association between newly diagnosed atrial fibrillation and wake-up ischemic cerebrovascular events. Methods: We prospectively assessed every acute ischemic stroke and TIA patient admitted to our hospital between 2008 and 2011. We used a […]
Atrial Fibrillation
Tuesday, April 23rd, 2013
CIRCEP: April 11, 2013 Background—Left atrial (LA) ganglionated plexi (GP) are part of the intrinsic cardiac autonomic nervous system and implicated in the pathogenesis of atrial fibrillation (AF). High frequency stimulation (HFS) is used to identify GP sites in humans. The effect of ablation on neural pathways connecting GPs in humans is unknown. Methods and Results—30 […]
Atrial Fibrillation
Tuesday, April 23rd, 2013
CIRCEP: April 11, 2013 Background—Pulmonary vein isolation (PVI) has increasingly been used to cure atrial fibrillation, but concerns have recently been raised that subclinical brain damage may occur due to microembolization during these procedures. We compared the occurrence of bubble formation seen on intracardiac echocardiography (ICE) and the microembolic signals (MESs) detected by transcranial Doppler on […]
Atrial Fibrillation
Tuesday, April 23rd, 2013
Circulation: Arrhythmia and Electrophysiology: February 26, 2013 Background—Ablation of high-frequency sources in patients with atrial fibrillation (AF) is an effective therapy to restore sinus rhythm. However, this strategy may be ineffective in patients without a significant dominant frequency (DF) gradient. The aim of this study was to investigate whether sites with high-frequency activity in human AF […]
Atrial Fibrillation
Wednesday, April 17th, 2013
American Journal of Cardiology: April 4, 2013 The progression of atrial fibrillation (AF) to a more sustained form is associated with increased symptoms and morbidity. The aims of the REgistry on Cardiac Rhythm DisORDers Assessing the Control of Atrial Fibrillation (RecordAF)–United States (US) cohort study were to identify the risk factors of AF progression and the […]
Atrial Fibrillation
Wednesday, April 17th, 2013
J Am Coll Cardiology: April 1, 2013 Objectives The purpose of this study was to investigate the associations of traditional risk factors and longitudinal measures of HIV disease severity with risk of incident atrial fibrillation (AF) in a contemporary cohort of HIV-infected individuals. Background Cardiovascular disease is common in HIV-infected persons; however, the most common cardiac arrhythmia, […]
Atrial Fibrillation
Wednesday, April 17th, 2013
J Am Coll Cardiology: April 1, 2013 Objective To assess the efficacy and safety in an ‘everyday clinical practice’ population of anticoagulant-naïve patients with atrial fibrillation (AF) treated with dabigatran etexilate following its post-approval availability in Denmark, compared to warfarin. Background Concerns have been raised about an excess of bleeding events or myocardial infarction amongst patients treated […]
Atrial Fibrillation
Wednesday, April 17th, 2013
J Am Coll Cardiology: April 1, 2013 Objective To assess the prognostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with atrial fibrillation (AF) enrolled in the ARISTOTLE trial, and the treatment effect of apixaban according to NT-proBNP levels. Background Natriuretic peptides are associated with mortality and cardiovascular events in several cardiac diseases. Read more
